Essential Pharma, a UK-based international specialty pharma group, announced on Thursday that it has completed two deals with United Kingdom-based Rosemont Pharmaceuticals, acompany focused on manufacturing oral liquid products.
Essential Pharma has completed the divestment of its oral liquid portfolio to Rosemont. Essential has separately acquired a series of products with geographic expansion potential.
According to the terms of the divestment, Rosemont Pharmaceuticals is acquiring the product portfolio of licences, registrations and trademarks, and related commercial rights, to various oral generic products that are used to treat a range of conditions in various therapeutic areas.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US